Андрогенный профиль пациенток с синдромом поликистозных яичников и его взаимосвязь с метаболической дисфункцией

1. Azziz R., Sanchez L.A., Knochenhauer E.S., Moran C., Lazenby J., Stephens K.C., Taylor K., Boots L.R. Androgen Excess in Women: Experience with Over 1000 Consecutive Patients. JCEM. 2004; 89(2): 453–462. https://doi.org/10.1210/jc.2003-031122
2. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004
3. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., Witchel S.F.; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006; 91(11): 4237-45. DOI: 10.1210/jc.2006-0178
4. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Franks S., Gambineri A., Kelestimur F., Macut D., Micic D., Pasquali R., Pfeifer M., Pignatelli D., Pugeat M., Yildiz B.; ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171(4): P1-29. doi: 10.1530/EJE-14-0253
5. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91:456–88. doi:10.1016/j.fertnstert.2008.06.035)
6. Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., Piltonen T., Norman R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 33(9): 1602–18. doi: 10.1093/humrep/dey256
7. Jones H., Sprung V.S., Pugh C.J., Daousi C, Irwin A., Aziz N., Adams V.L., Thomas E.L., Bell J.D., Kemp G.J., Cuthbertson D.J. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic pcos phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012; 97(10): 3709–16. doi:10.1210/jc.2012-1382
8. Чернуха Г.Е., Блинова И.В., Купрашвили М.И. Эндокринно-метаболические характеристики больных с различными фенотипами синдрома поликистозных яичников. Акушерство и гинекология. 2011; 2: 70-76.
9. Cakir E1, Doğan M, Topaloglu O, Ozbek M, Cakal E, Vural MG, Yeter E, Delibasi T. Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism. Atherosclerosis. 2013; 226: 291–295. doi: 10.1016/j.atherosclerosis.2012.11.004.
10. Lerchbaum E., Schwetz V., Rabe T., Giuliani A., Obermayer-Pietsch B. Hyperandrogenemia in Polycystic Ovary Syndrome: Exploration of the Role of Free Testosterone and Androstenedione in Metabolic Phenotype. PLoS One. 2014; 9(10): e108263. doi: 10.1371/journal.pone.0108263
11. Georgopoulos N.A., Papadakis E., Armeni A.K., Katsikis I., Roupas N.D., Panidis D. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens). 2014; 13(2): 213-21. DOI: 10.1007/BF03401335
12. Ruan X., Li M., Mueck A.O. Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management? Curr Pharm Des. 2018; 24(39): 4685-92. doi: 10.2174/1381612825666190130104922
13. Zhu S., Zhang B., Jiang X., Li Z, Zhao S., Cui L., Chen Z.J. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019;111(1):168-177. doi: 10.1016/j.fertnstert.2018.09.013
14. Ананьев Е.В. Синдром поликистозных яичников и беременность. Акушерство и гинекология. 2017; 9: 5-11.
15. Ciaraldi T.P., Aroda V., Mudaliar S., Chang R.J., Henry R.R. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J. Clin. Endocrinol. Metab. 2009; 94(1):157–63. DOI: 10.1210/jc.2008-1492
16. Højlund K., Glintborg D. Andersen N.R., Birk J.B., Treebak J.T., Frøsig C., Beck-Nielsen H., Wojtaszewski J.F. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes. 2008; 57(2):357–66. DOI: 10.2337/db07-0706
17. O’Reilly M.W., Taylor A.E., Crabtree N.J., Hughes B.A., Capper F., Crowley R.K., Stewart P.M., Tomlinson J.W., Arlt W. Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. J Clin Endocrinol Metab. 2014; 99(3): 1027–36. doi: 10.1210/jc.2013-3399
18. Мамедов М.Н., Поддубская Е.А. Диагностика и лечение ранних нарушений углеводного обмена в общетерапевтической практике (методические рекомендации). ФГУ ГНИ ЦПМ. М.; 2011. 36 с.

Поступила 15.04.2019

Принята в печать 19.04.2019